Anavex Life Sciences (NASDAQ:AVXL) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL) issued its earnings results on Wednesday. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Stock Performance

Shares of NASDAQ AVXL opened at $8.47 on Friday. The stock has a market cap of $718.43 million, a PE ratio of -16.29 and a beta of 0.69. The business has a fifty day moving average of $9.94 and a two-hundred day moving average of $7.70. Anavex Life Sciences has a 52-week low of $3.25 and a 52-week high of $14.44.

Analyst Ratings Changes

Several research analysts recently commented on AVXL shares. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, January 28th. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Wednesday.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.